Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Invested Capital (2020 - 2025)

Historic Invested Capital for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to $31.5 million.

  • Journey Medical's Invested Capital rose 264.4% to $31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.5 million, marking a year-over-year increase of 264.4%. This contributed to the annual value of $44.9 million for FY2024, which is 2852.57% up from last year.
  • As of Q3 2025, Journey Medical's Invested Capital stood at $31.5 million, which was up 264.4% from $23.0 million recorded in Q2 2025.
  • Journey Medical's 5-year Invested Capital high stood at $56.2 million for Q1 2022, and its period low was -$11.7 million during Q3 2021.
  • Moreover, its 5-year median value for Invested Capital was $31.0 million (2024), whereas its average is $31.3 million.
  • Its Invested Capital has fluctuated over the past 5 years, first tumbled by 27161.07% in 2021, then skyrocketed by 49272.35% in 2022.
  • Journey Medical's Invested Capital (Quarter) stood at $42.9 million in 2021, then grew by 4.41% to $44.7 million in 2022, then fell by 21.85% to $35.0 million in 2023, then rose by 28.53% to $44.9 million in 2024, then fell by 29.87% to $31.5 million in 2025.
  • Its Invested Capital stands at $31.5 million for Q3 2025, versus $23.0 million for Q2 2025 and $23.4 million for Q1 2025.